MeMeds COVID-19 Severity Test erhält die CE-Kennzeichnung für die Vorhersage von schwerwiegenden Krankheitsverläufen bei COVID-19-Patienten*innen
27. Juli 2021 02:00 ET
|
MeMed
MeMeds COVID-19 Severity Test erhält die CE-Kennzeichnung für die Vorhersage von schwerwiegenden Krankheitsverläufen bei COVID-19-Patienten*innenDer MeMed COVID-19 Severity™ Test analysiert das...
MeMed Key® Wins Red Dot Award for High Design Quality
22. April 2021 07:00 ET
|
MeMed
MeMed Key® Wins Red Dot Award for High Design Quality HAIFA, April 22, 2021- frog, a leading global design and strategy consultancy, part of...
MeMed and 360Dx Bring Together International Experts for a Timely Discussion on Predicting COVID-19 Severity Using the Host Immune Response
13. April 2021 07:00 ET
|
MeMed
MeMed and 360Dx Bring Together International Experts for a Timely Discussion on Predicting COVID-19 Severity Using the Host Immune Response HAIFA, Israel, April 13, 2021 – MeMed, a leader in...
Troy Boutelle Joins MeMed as Vice President of Commercial in North America and General Manager, U.S.
12. Januar 2021 07:00 ET
|
MeMed
Troy Boutelle Joins MeMed as Vice President of Commercial in North America and General Manager, U.S. Troy brings 20 years of top-flight sales and commercial experience as MeMed expands into the U.S....
MeMed Appoints Industry Veteran Chris Hibberd to its Board of Directors
16. Dezember 2020 07:12 ET
|
MeMed
MeMed Appoints Industry Veteran Chris Hibberd to its Board of Directors HAIFA, Israel, December 16, 2020 – MeMed, a leader in host immune response-based solutions, today announced that Chris Hibberd...
MeMed Selected to Present at BARDA Industry Day 2020
26. Oktober 2020 07:00 ET
|
MeMed
MeMed Selected to Present at BARDA Industry Day 2020 Dr. Eran Eden to Give Lightning Talk on October 27 on MeMed’s Advanced Host-Immune Response Technology HAIFA, Israel, October 26, 2020 – MeMed™,...
DiaSorin and MeMed partner to develop and commercialize novel host immune response based diagnostics solution
08. September 2020 07:00 ET
|
MeMed
DiaSorin and MeMed partner to develop and commercialize novel host immune response based diagnostics solution ...
DiaSorin 与 MeMed 合作开发和商业化基于新型宿主免疫应答的诊断解决方案
08. September 2020 02:02 ET
|
MeMed
DiaSorin 与 MeMed 合作开发和商业化基于新型宿主免疫应答的诊断解决方案 ...
הישראלית חתמו על MeMed-ו DiaSorin שיתוף פעולה אסטרטגי
08. September 2020 01:30 ET
|
MeMed
הודעה לעיתונות הישראלית חתמו על MeMed-ו DiaSorin שיתוף פעולה אסטרטגי הבדיקה שפיתחה MeMed, המבחינה בין זיהומים ויראלים לחיידקיים במהירות ובדיוק רב, תשולב בתפריט פלטפורמת הבדיקות של החברה...
DiaSorin and MeMed partner to develop and commercialize novel host immune response based diagnostics solution
08. September 2020 01:30 ET
|
MeMed
DiaSorin and MeMed partner to develop and commercialize novel host immune response based diagnostics solution ...